Segment Information (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Net Sales and Segment Contribution for Each Reportable Segment

Net sales and segment contribution by each reportable segment for the three months ended September 30, 2023 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	80,376	$	—	$	1,336	$	81,712
Cost of sales	13,305		—		1,485		14,790
Selling, general and administrative expense	38,687		—		13,884		52,571
Research and development expense	3,175		—		—		3,175
Restructuring	—		208		—		208
Amortization of intangible assets	—		—		190		190
Segment contribution	$	25,209	$	(208)
Investigation, restatement and related expense							(38)
Operating income							$	10,816
Supplemental information
Depreciation expense	$	423	$	—	$	230	$	653
Share-based compensation	$	1,902	$	—	$	2,486	$	4,388

Net sales and segment contribution by each reportable segment for the three months ended September 30, 2022 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	66,873	$	—	$	816	$	67,689
Cost of sales	11,159		—		1,029		12,188
Selling, general and administrative expense	35,530		—		17,945		53,475
Research and development expense	1,680		4,273		—		5,953
Amortization of intangible assets	—		—		175		175
Segment contribution	$	18,504	$	(4,273)
Investigation, restatement and related expense							3,001
Operating loss							$	(7,103)
Supplemental information
Depreciation expense	$	451	$	36	$	344	$	831
Share-based compensation	$	1,945	$	347	$	80	$	2,372

Net sales and segment contribution by each reportable segment for the nine months ended September 30, 2023 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	231,466	$	—	$	3,179	$	234,645
Cost of sales	37,373		—		3,419		40,792
Selling, general and administrative expense	114,853		—		41,920		156,773
Research and development expense	6,330		11,838		—		18,168
Restructuring	—		3,464		—		3,464
Amortization of intangible assets	—		—		570		570
Segment contribution	$	72,910	$	(15,302)
Investigation, restatement and related expense							4,652
Operating income							$	10,226
Supplemental information
Depreciation expense	$	1,208	$	135	$	711	$	2,054
Share-based compensation	$	5,130	$	259	$	7,404	$	12,793

Net sales and segment contribution by each reportable segment for the nine months ended September 30, 2022 were as follows (in thousands):

	Wound & Surgical		Regenerative Medicine		Corporate & Other		Consolidated
Net sales	$	191,297	$	—	$	2,169	$	193,466
Cost of sales	31,126		—		2,821		33,947
Selling, general and administrative expense	108,256		—		50,582		158,838
Research and development expense	6,068		11,361		—		17,429
Amortization of intangible assets	—		—		519		519
Segment contribution	$	45,847	$	(11,361)
Investigation, restatement and related expense							8,771
Operating loss							$	(26,038)
Supplemental information
Depreciation expense	$	1,364	$	120	$	1,065	$	2,549
Share-based compensation	$	5,609	$	910	$	4,279	$	10,798